Amplification of human platelet activation by surface pannexin-1 channels

K. A. TAYLOR, J. R. WRIGHT, C. VIAL, R. J. EVANS and M. P. MAHAUT-SMITH
Department of Cell Physiology and Pharmacology, University of Leicester, Leicester, UK

To cite this article: Taylor KA, Wright JR, Vial C, Evans RJ, Mahaut-Smith MP. Amplification of human platelet activation by surface pannexin-1 channels. J Thromb Haemost 2014; 12: 987–98.

Summary. Background: Pannexin-1 (Panx1) forms an anion-selective channel with a permeability up to ~1 kDa and represents a non-lytic, non-vesicular ATP release pathway in erythrocytes, leukocytes and neurons. Related connexin gap junction proteins have been reported in platelets; however, the expression and function of the pannexins remain unknown. Objective: To determine the expression and function of pannexins in human platelets, using molecular, cellular and functional techniques. Methods: Panx1 expression in human platelets was determined using qPCR and antibody-based techniques. Contributions of Panx1 to agonist-evoked efflux of cytoplasmic calcein, Ca^{2+} influx, ATP release and aggregation were assessed in washed platelets under conditions where the P2X1 receptor response was preserved (0.32 U mL^{-1} apyrase). Thrombus formation in whole blood was assessed in vitro using a shear chamber assay. Two structurally unrelated and widely used Panx1 inhibitors, probenecid and carbeneoxolone, were used throughout this study, at concentrations that do not affect connexin channels. Results: PANX1, but not PANX2 or PANX3, mRNA was detected in human platelets. Furthermore, Panx1 protein is glycosylated and present on the plasma membrane of platelets, and displays weak physical association with P2X1 receptors. Panx1 inhibition blocked thrombin-evoked efflux of calcein, and reduced Ca^{2+} influx, ATP release, platelet aggregation and thrombus formation under arterial shear rates in vitro. The Panx1-dependent contribution was not additive to that of P2X1 receptors. Conclusions: Panx1 is expressed on human platelets and amplifies Ca^{2+} influx, ATP release and aggregation through the secondary activation of P2X1 receptors. We propose that Panx1 represents a novel target for the management of arterial thrombosis.

Keywords: ATP; calcium; collagen; P2X1 receptor; pannexin 1, human.

Introduction

Recent studies have identified the presence of connexin gap junction proteins in platelets, with important roles reported for connexins 37 and 40 [1–3]. Connexins were originally identified as the mammalian homologues of the invertebrate gap junction family, the innexins [4]. Panchin et al. [5] discovered a further family of three proteins with >20% sequence similarity to the innexins [4], named pannexins 1, 2 and 3 (Panx1/2/3). Expression profiling of the pannexin family has revealed that Panx1 is ubiquitously expressed whereas Panx2 is predominantly expressed in the brain and CNS, whilst Panx3 has only been detected in bone and skin [6].

Panx1 subunits are glycosylated at Asn254 before being trafficked to the plasma membrane, where they form Anion-selective hexameric ion channels with a permeability up to ~1 kDa [7–11]. Panx1 opening has been shown in response to mechanical stress [11], oxygen-glucose deprivation [12], caspase cleavage [13] and an increase in [Ca^{2+}] [14]. ATP release through Panx1 channels represents a mechanism for the activation of ATP-gated P2X1, 4 and 7 receptors in T cells [15], erythrocytes [16] and neurons [17]. The P2X1 receptor is the only member of this family of ATP-gated channels that is functional in platelets [18] and contributes to Ca^{2+} influx following stimulation by several major agonists [19,20]. In vitro and in vivo studies [21] have identified an important role for P2X1 cation channels in thrombus formation, particularly under high shear. The mechanism(s) whereby P2X1 receptors are activated following stimulation by collagen or other primary platelet agonists is incompletely understood; however, evidence suggests a predominantly autocrine mechanism of activation by released ATP [22].
Here we demonstrate that human platelets express functional Panx1 channels, which represent a novel, non-vesicular mechanism of ATP release that amplifies aggregation and Ca\textsuperscript{2+} influx at low concentrations of several major platelet agonists.

Materials and methods

Reagents

Collagen type I from bovine tendon was a gift from the Ethicon Corporation (Somerville, NJ, USA) and hrom collagen from equine tendon was purchased from Alere (Stockport, Cheshire, UK), U46619 and thapsigargin were purchased from Calbiochem (Nottingham, Nottinghamshire, UK), and NF449 from Tocris (Bristol, UK). All other reagents were from Sigma (Gillingham, Dorset, UK). Probenecid (Prb) was prepared in normal platelet saline (NPS: in mM; 145 NaCl, 5 KCl, 1 MgCl\textsubscript{2}, 10 D-glucose, 10 HEPES –3.5 NaOH, pH 7.35) as described previously [23].

Preparation of washed human platelets

The study was approved by the University of Leicester Committee for Research Ethics concerning human subjects (non-NHS). Blood was collected into acid citrate dextrose anticoagulant (ACD; 85 mM trisodium citrate, 78 mM citric acid and 111 mM glucose) from informed, consenting donors in accordance with the Declaration of Helsinki. The blood : ACD mix (6:1) was centrifuged at 180 x g, 20 min), and the top two-thirds were removed and treated with 2 mM EDTA, 0.1 mA PGE\textsubscript{1} and 0.3 mA aspirin. Residual leukocytes and erythrocytes were removed by immunomagnetic depletion [25]. mRNA was isolated using oligo-dT magnetic beads (Invitrogen) and reverse transcribed using AMV-RT (Invitrogen) as per the manufacturer’s instructions. cDNA samples were screened for platelet Panx1 (Fig. S2). Transfection into human embryonic kidney-293 (HEK-293) cells and positive selection with geneticin (0.6 mg mL\textsuperscript{-1}; Invitrogen) generated a stable hPanx1-His-FLAG HEK-293 cell line.

Western blotting

Western blotting was performed as described previously [26], using antibodies listed in Table S1. For deglycosylation experiments protein lysates were treated with 750
units of PNGaseF (NEB, Ipswich, MA, USA) for 1 h at 37 °C before SDS-PAGE.

Co-immunoprecipitation

Whole platelet lysates (1 mg mL\(^{-1}\)) were centrifuged (15 700 \(\times\) g, 10 min, 4 °C) to pellet the actin cytoskeleton. The retained supernatants were preclarified for 1 h at 4 °C with protein-A (P2X1R) or protein-G (Panx1) agarose. Agarose beads were pelleted (15 700 \(\times\) g, 2 min, 4 °C) and the supernatant retained. One microgram per milliliter of α-P2X1R or α-Panx1 antibody was added (2 h, 4 °C) before adding protein-A/G agarose to the respective samples overnight. Beads were washed three times (15 700 \(\times\) g, 2 min, 4 °C) with 1xRIPA lysis buffer (150 mM NaCl, 50 mM Tris base, 0.5% [w/v] sodium deoxycholate, 0.1% [w/v] SDS, 1% Triton X-100, pH 8.0 with HCl) and once with 1xTBS-T (2 mM Tris base, 13.7 mM NaCl, 0.01% Tween-20, pH 7.6 with HCl) before SDS-PAGE.

Platelet membrane biotinylation

Platelet biotinylation was performed as described previously [27]. Total and streptavidin IP (surface) samples were analyzed by western blot for Panx1 and ERK1/2. Surface expression of Panx1 was quantified relative to the cytosolic protein ERK1/2, by densitometry (Image-J v1.45s, National Institutes of Health, Bethesda, MD, USA).

Immunocytochemistry

Immunocytochemistry was performed as described previously [28]. Cells were incubated with 4 μg mL\(^{-1}\) anti-Panx1 antibody (overnight, 4 °C). Following incubation with Alexafluor-647-conjugated anti-goat secondary antibody (30 min; 1 : 1000; Invitrogen), fluorescence was assessed at 635 nm excitation (650-750 nm emission) using an Olympus FV1000 confocal microscope. HEK-293 cells were fixed onto coverslips, whilst platelets were assessed at 635 nm excitation (650-750 nm emission) using an Olympus FV1000 confocal microscope. HEK-293 cells and platelets. We observed full-length Panx1 (48 kDa) in native HEK-293 cells and platelets and a 50 kDa band in hPanx1-His-FLAG HEK-293 (Fig. 1C), as predicted from a 2 kDa His-FLAG tag within the construct (Fig. S2). To further investigate Panx1 localization in platelets, we performed surface biotinylation experiments. The relative density of Panx1 to that of the cytosolic protein ERK1/2 in the total and surface lanes was determined by densitometry, which showed a 4.3-fold enhancement of Panx1:ERK1/2 for biotinylated proteins (Fig. 1D). Panx1 has previously been shown to be glycosylated on its second extracellular loop, giving rise to the fully glycosylated (48 kDa) and unglycosylated (~37 kDa) species, with only the former present at the plasma membrane [7,8]. Consistent with these previous studies, the Panx1 band in platelets (48 kDa) and hPanx1-His-FLAG HEK-293 cells (50 kDa) was reduced to ~37 kDa and ~39 kDa, respectively, after treatment with the glycosidase, PNGaseF (Fig. 1E). Together with the immunocytochemical and biotinylation data, this suggests that Panx1 is predominantly located on the surface membrane of human platelets.

Statistical analysis

Platelet aggregation, ATP release and [Ca\(^{2+}\)]\(_i\) measurements were normalized as a percentage of a paired control response. Data are presented as the mean ± SEM. Significance was determined using either the Student paired t-test or ANOVA with Bonferroni post-testing within GraphPad Prism 5 as appropriate and indicated as not significant (ns), \(P < 0.05\)*, \(P < 0.01**\) and \(P < 0.001***\).

Results

Pannexin-1 is expressed on the surface of human platelets

Purified human platelet mRNA was reverse transcribed and screened by qPCR for PAXN1, PANX2 and PANX3, along with P2RX1, the ubiquitously expressed Na\(^+\)/K\(^+\) ATPase (ATP1A1) and the platelet-specific receptor GP1BB. Gene expression was quantified relative to the detection level of β-actin (ACTB). PAXN1 mRNA was present in platelets at a similar level to P2RX1 (Fig. 1A), whereas PANX2 and PANX3 were not detected (not shown). Panx1 protein expression has previously been reported in HEK-293 cells using an anti-Panx1 antibody raised against its C-terminus [30]. Immunocytochemistry using this antibody demonstrated strong fluorescence for Panx1 at the periphery of both hPanx1-His-FLAG HEK-293 cells and platelets (Fig. 1B; the inset images show that no fluorescence was detected from secondary antibody controls). Western blotting of Panx1 protein expression was performed for native and hPanx1-His-FLAG HEK-293 cells and platelets. We observed full-length Panx1 (48 kDa) in native HEK-293 cells and platelets and a 50 kDa band in hPanx1-His-FLAG HEK-293 (Fig. 1C), as predicted from a 2 kDa His-FLAG tag within the construct (Fig. S2). To further investigate Panx1 localization in platelets, we performed surface biotinylation experiments. The relative density of Panx1 to that of the cytosolic protein ERK1/2 in the total and surface lanes was determined by densitometry, which showed a 4.3-fold enhancement of Panx1:ERK1/2 for biotinylated proteins (Fig. 1D). Panx1 has previously been shown to be glycosylated on its second extracellular loop, giving rise to the fully glycosylated (48 kDa) and unglycosylated (~37 kDa) species, with only the former present at the plasma membrane [7,8]. Consistent with these previous studies, the Panx1 band in platelets (48 kDa) and hPanx1-His-FLAG HEK-293 cells (50 kDa) was reduced to ~37 kDa and ~39 kDa, respectively, after treatment with the glycosidase, PNGaseF (Fig. 1E). Together with the immunocytochemical and biotinylation data, this suggests that Panx1 is predominantly located on the surface membrane of human platelets.
Pannexin-1 modulates platelet Ca\textsuperscript{2+} influx evoked by multiple agonists

Locovei et al. [14] demonstrated that Panx1 can be activated by an increase in intracellular Ca\textsuperscript{2+} concentration, resulting in ATP release and amplification of Ca\textsuperscript{2+} responses in oocytes co-expressing Panx1 and P2Y1 receptors. We therefore examined the contribution of Panx1 to Ca\textsuperscript{2+} influx evoked by low concentrations of the major platelet agonists collagen (0.5 \mu g L\textsuperscript{-1}), thrombin (0.03 U mL\textsuperscript{-1}), and the TXA\textsubscript{2} analogue U46619 (500 nM), which all rely on secondary activation of P2X1 receptors to amplify the Ca\textsuperscript{2+} response [20]. The collagen-evoked Ca\textsuperscript{2+} response was reduced to 67.3 \pm 4.9\% (n = 8, P < 0.001) and 69.1 \pm 2.1\% (n = 5, P < 0.001) of control responses by Prb and Cbx, respectively (Fig. 2A,D). These two structurally unrelated and widely used Panx1 blockers [10, 31] were applied at concentrations (100 \mu M Prb and 10 \mu M Cbx) that do not affect connexin channels reported in platelets [1,3,30,32]. Inhibition of Panx1 caused a similar reduction of thrombin-evoked Ca\textsuperscript{2+} influx, to 68.2 \pm 4.5\% (n = 6, P < 0.01) and 77.5 \pm 2.8\% (n = 5, P < 0.001) of control by Prb and Cbx, respectively (Fig. 2B,D). Finally, U46619 Ca\textsuperscript{2+} responses were also reduced to 79.3 \pm 3.0\% of control (n = 6, P < 0.001) by Prb and 74.7 \pm 2.8\% of control (n = 5, P < 0.001) by Cbx (Fig. 2C,D). For each agonist, there was no significant difference between the reductions caused by the two inhibitors (P > 0.05, Fig. 2D).

Panx1 channel opening has previously been assessed by influx or efflux of cell-impermeant indicators < 1 kDa in size [12,33]. For platelets, we used flow cytometry to measure efflux of calcein, an anionic 0.62 kDa fluorescent indicator, from the platelet cytosol (Fig. 3). Thrombin...
stimulated a loss of calcein fluorescence, which was not observed in unstimulated cells and was blocked by Panx1 inhibitors (Fig. 3B). After 300 s, thrombin caused 31.4%/C6 10.4% (n = 4, P < 0.001) of events to move from gate F1; this loss of fluorescence was completely blocked by pre-incubation with either Prb or Cbx (102.1 ± 1.7% and 101.1 ± 1.2%, respectively, compared with 107.7 ± 6.7% in unstimulated cells, P > 0.05; Fig. 3C). This provides further evidence that platelets express functional anion-permeable Panx1 channels on their surface, which are opened by a physiological agonist.

Panx1 could influence platelet Ca\(^{2+}\) responses by modulation of either Ca\(^{2+}\) release or a plasma membrane Ca\(^{2+}\) entry pathway. There was no significant effect of Prb or Cbx on agonist-evoked Ca\(^{2+}\) store release in the absence of external Ca\(^{2+}\) (Fig. S3), suggesting that Panx1 acts at the plasma membrane, consistent with its

---

**Fig. 2.** Pannexin-1 modulates Ca\(^{2+}\) influx response to multiple agonists. Platelets were stimulated with 0.5 \(\mu\)g mL\(^{-1}\) collagen (A), 0.03 U mL\(^{-1}\) thrombin (B) or 500 nM U46619 (C) in the presence or absence of either 100 \(\mu\)M Prb (left panel) or 10 \(\mu\)M Cbx (right panel). (D) Peak Ca\(^{2+}\) responses were normalized to paired vehicle control (saline or 0.2% DMSO). Representative traces are from paired-control runs from individual donors and representative of at least five independent experiments.

**Fig. 3.** Thrombin-evoked efflux of the anionic dye calcein is blocked by Panx1 inhibitors. (A) Washed platelets were selected using forward and side scatter properties to include >90% of events in resting (left) and thrombin (0.03 U mL\(^{-1}\))-stimulated (right) conditions. (B) Histograms of calcein fluorescence at t = 0 s (black) and t = 300 s (red) for either unstimulated platelets (Unstim.), platelets stimulated by thrombin (Thr), platelets stimulated by thrombin in the presence of 100 \(\mu\)M Prb (Thr + Prb) or platelets stimulated by thrombin in the presence of 10 \(\mu\)M Cbx (Thr + Cbx). (C) The percentage reduction in the proportion of cells within F1 was calculated at each 60 s time-point and is expressed relative to 0 s. Inhibitor-free runs for unstimulated and thrombin-stimulated conditions contained 0.5% DMSO as the vehicle control. Data are representative of five independent experiments.
predominant location (Fig. 1). Store-operated Ca\(^{2+}\) entry (SOCE) and P2X1 receptors represent the main plasma membrane Ca\(^{2+}\) entry pathways at the low agonist concentrations used in this study [20,34]. Neither Prb nor Cbx had any significant effect on SOCE activated by thapsigargin (Fig. S4) or P2X1 receptors directly activated by \(\alpha,\beta\)-meATP (10 \(\mu\)M, Fig. S5). Our findings therefore suggest a role for Panx1 in Ca\(^{2+}\) influx across the plasma membrane, most likely by autocrine activation of P2X1 receptors by released ATP. This possibility is explored below.

**Pannexin-1 amplifies collagen-evoked ATP release and platelet aggregation**

To determine if Panx1 contributes to platelet activation through P2X1 receptor stimulation we assessed platelet aggregation and ATP release to 0.5 \(\mu\)g mL\(^{-1}\) collagen, which requires amplification by P2X1 receptors [19–22, 35]. Platelet ATP release measured by luciferin:luciferase was reduced to 18.2 ± 5.7% \((n = 4, \text{ } P < 0.001)\) and 14.7 ± 8.6% \((n = 4, \text{ } P < 0.001)\) of the paired control response by Prb and Cbx, respectively (Fig. 4A). Aggregation was also reduced by Prb and Cbx to 16.2 ± 3.3% \((n = 4, \text{ } P < 0.001)\) and 12.6 ± 2.4% \((n = 4, \text{ } P < 0.001)\) of the control response, respectively (Fig. 4A). Figure 7 shows that the collagen-evoked ATP release precedes the aggregation response. The contribution of P2X1 receptors to platelet ATP release and aggregation under the conditions of our experiments was assessed by selectively desensitizing the receptor with 0.6 \(\mu\)M \(\alpha,\beta\)-meATP in NPS prior to addition of external Ca\(^{2+}\) and agonist [20]. Under these conditions ATP release and aggregation (Fig. 4A) to 0.5 \(\mu\)g mL\(^{-1}\) collagen were reduced to 25.1 ± 3.6% \((n = 4, \text{ } P < 0.001)\) and 15.3 ± 4.5% \((n = 4, \text{ } P < 0.001)\) of paired control responses, respectively. We also examined the effect of Panx1 inhibition following stimulation by high collagen concentrations, where \(\alpha,\beta\)-meATP pre-addition caused smaller or no significant effects; 80.8 ± 4.3% \((n = 4, \text{ } P < 0.05)\) and 92.5 ± 5.6% \((n = 4, \text{ } P > 0.05)\), of control aggregation responses at 5 and 10 \(\mu\)g mL\(^{-1}\) collagen, respectively (Fig. 4B-D).

![Fig. 4. Pannexin-1 amplifies ATP release and platelet aggregation at low collagen concentrations through activation of P2X1 receptors. Representative collagen-evoked platelet ATP release (left) and aggregation (right) responses to 0.5 \(\mu\)g mL\(^{-1}\) (A), 5 \(\mu\)g mL\(^{-1}\) (B) or 10 \(\mu\)g mL\(^{-1}\) (C) collagen. Overlaid traces show responses from control (black), 10 \(\mu\)M Cbx (blue) or 0.6 \(\mu\)M \(\alpha,\beta\)-meATP (grey) treated platelets. Average responses from four independent donors are shown as a percentage of paired control response (D) for Prb (red), Cbx (blue) and \(\alpha,\beta\)-meATP (grey).](image-url)
Likewise, collagen-evoked ATP release was only moderately reduced by desensitization of P2X1 receptors, with peak responses of $81.1 \pm 3.1\%$ ($n = 4, P < 0.05$) at 5 $\mu$g mL$^{-1}$ and no effect at 10 $\mu$g mL$^{-1}$ ($104.1 \pm 3.9\%, n = 4, P > 0.05$). Panx1 inhibition had no significant effect on ATP release or aggregation in response to stimulation with 10 $\mu$g mL$^{-1}$ collagen (Fig. 4C,D; $n = 4, P > 0.05$), and an intermediate effect was observed at 5 $\mu$g mL$^{-1}$ collagen (Fig. 4B,D). These studies are consistent with a requirement for P2X1 receptors to observe the contribution of Panx1 in platelet functional responses. In addition, it suggests that Panx1 has a more important role in ATP release and platelet function upon stimulation by low concentrations of agonist.

At the level of Ca$^{2+}$ mobilization, abolition of P2X1 receptor responses by pre-desensitization with 0.6 $\mu$m $\alpha$-meATP [20], reduced the collagen-evoked Ca$^{2+}$ increase to $33.2 \pm 3.1\%$ ($n = 5, P < 0.001$) of the control response, consistent with previous findings [19] (Fig. 5). No further decrease was observed following co-addition of Prb with $\alpha$-$\beta$-meATP ($23.3 \pm 3.3\%, n = 5, P = 0.13$) or Cbx with $\alpha$-$\beta$-meATP ($21.3 \pm 3.5\%, n = 5, P = 0.08$). We hypothesized that Panx1 may represent a route for generating localized ATP release and thus efficient, autocrine activation of P2X1 receptors. One possibility is that the two proteins are physically interacting, which we assessed by co-immunoprecipitation experiments. We observed a weak, but consistent interaction between P2X1 receptors and Panx1 in unstimulated platelet lysates (Fig. S6A). Densitometry shows a stronger signal for Panx1 when the P2X1 receptor was immunoprecipitated than vice-versa: $0.373 \pm 0.027$ vs. $0.152 \pm 0.068$ ($P < 0.001$, Fig. S6C). This stoichiometry could reflect the quaternary structure of Panx1 channels and P2X1 receptors, which form hexamers and trimers, respectively.

**Pannexin-1 is activated under arterial shear conditions in vitro**

Previous studies have demonstrated Panx1 activation in response to mechanical stress [11,36]; therefore we examined its contribution to thrombus formation under flow conditions. Percentage surface coverage, thrombus volume and thrombus height were assessed by flowing whole blood over collagen-coated coverslips at an arterial shear rate of 1000 s$^{-1}$ [29]. Surface coverage of platelets was only slightly reduced by Prb (7.5 $\pm$ 2.5%, $n = 5, P < 0.05$) and not affected by Cbx (2.9 $\pm$ 1.8%, $n = 4, P > 0.05$) (Fig. 6A–B). However, total thrombus volume (Fig. 6C) was reduced from 29 520 $\pm$ 4091 to 15 746 $\pm$ 3794 $\mu$m$^3$ ($n = 5, P < 0.01$) by Prb and from 29 914 $\pm$ 3958 to 19 886 $\pm$ 3344 $\mu$m$^3$ by Cbx ($n = 4, P < 0.05$). Furthermore, we observed a reduction in the mean thrombus height from 0.72 $\pm$ 0.10 mm to 0.40 $\pm$ 0.08 mm ($n = 5, P < 0.05$) by Prb and from 0.73 $\pm$ 0.10 to 0.49 $\pm$ 0.08 mm ($n = 4, P < 0.05$) by Cbx (Fig. 6D). These data suggest that Panx1 has a minor role in the initial adhesion events to a collagen-coated surface, but has a greater contribution to subsequent thrombus formation under flow conditions experienced in the arterial circulation. The selective P2X1 receptor antagonist NF449 (1 $\mu$m) reduced thrombus volume and height to the same extent as Panx1 inhibition (from 33 780 $\pm$ 3820 to 23 152 $\pm$ 1219 $\mu$m$^3$ [$n = 3, P < 0.05$] and 0.8240 $\pm$ 0.09 to 0.5647 $\pm$ 0.03 $\mu$m, respectively [$n = 3, P < 0.05$; Fig. S7]). Furthermore, co-application of NF449 with Prb did not cause a further reduction beyond the effect observed with Prb alone (20 378 $\pm$ 3212 vs. 20 594 $\pm$ 5567 $\mu$m$^3$; $n = 3, P > 0.05$) and (0.50 $\pm$ 0.08 vs. 0.50 $\pm$ 0.14 $\mu$m; $n = 3, P > 0.05$) for thrombus volume and height, respectively.

**Discussion**

This study shows for the first time that Panx1 anion-permeable channels are expressed on human platelets.
mRNA transcripts for PANX1, but not other mammalian pannexin subtypes, were detected in purified populations of platelets at similar levels to those of another ion channel (P2X1 receptor), which has established roles in thrombosis. Furthermore, glycosylation, biotinylation and immunocytochemistry experiments demonstrated that platelet Panx1 protein is fully processed and present at the plasma membrane (Fig. 1). Glycosylation at the second extracellular loop of Panx1 [9] prevents opposed Panx1 channels from docking to form gap junctions [8]. Thus, it is likely that Panx1 serves a different role to that reported for connexin 37 and 40 in platelets [1–3]. It is well established that platelets secrete ATP and ADP from dense granules in a Ca²⁺ [37] and PKC- [38] dependent manner, resulting in important amplification of platelet responses through P2X and P2Y receptors. Panx1 is known to serve as an ATP release pathway [15–17]; this channel therefore represents a novel pathway for ATP release from the platelet cytosol. Consistent with this suggestion, thrombin stimulated efflux of calcein, an anion permeable through Panx1 channels [12,33] and only slightly larger than ATP, which was blocked by Panx1 inhibitors (Fig. 3). Furthermore, Panx1 inhibitors reduced ATP release following stimulation by low collagen concentrations (Fig. 4A). Precisely how Panx1 is activated in platelets is presently unclear. A consensus sequence for PKC phosphorylation has been identified within its C-terminus that may influence channel gating [39]. However, the established role of PKC in secretion from dense granules prevented us from using inhibitors to assess the relative contribution of PKC to Panx1-mediated ATP release. Furthermore, although caspase-3 has been suggested previously to activate Panx1 in HEK-293 cells [13], the caspase inhibitor z-VAD-fmk had no effect on platelet aggregation and ATP responses (data not shown). An increase in cytosolic Ca²⁺, as shown in an oocyte expression system [14], remains a possible mechanism of Panx1 activation in platelets given the contribution to signaling we observed downstream of multiple receptor types.

Throughout this study we have relied upon the use of two inhibitors, which are not totally selective for Panx1 channels. However, we selected concentrations of these drugs that have been shown to block Panx1 activity in patch clamp studies and which do not affect other known targets, namely connexin hemichannels (Cbx) or anion transporters (Prb) [31,32,40,41]. Furthermore, connexin
hemichannels are closed under the conditions of our experiments (2 mM extracellular CaCl₂) [42–46], therefore we would not expect them to contribute to the ATP release or Ca²⁺ movements observed. Prb and Cbx also blocked calcein dye efflux (Fig. 3), consistent with previous studies of Panx1 function [12,33]. Nevertheless, it would be useful in future studies to assess the contribution of platelet Panx1 to hemostasis and thrombosis using an in vivo murine model and mice with Panx1-deficient platelets. Given the presence of Panx1 in a number of blood cell types [15,47], it will be crucial to develop a mouse line in which altered expression of this channel is specifically targeted to the platelet and megakaryocyte lineage.

Electrophysiological studies have demonstrated that Panx1 is an anion-selective channel [10] and is therefore unlikely to directly generate Ca²⁺ influx. Intracellular Ca²⁺ release was unaffected by Panx1 inhibitors and neither SOCE nor direct activation of P2X1 receptors were affected. In addition, at the low agonist concentrations used in this study, TRPC6 does not significantly contribute to Ca²⁺ entry [48]. Therefore, given that Prb and Cbx reduce collagen-evoked ATP release, it is likely that Prb and Cbx inhibit Ca²⁺ increases via reduction of secondary P2X1 receptor activation. The non-additive effect of Panx1 and P2X1 receptor blockade on collagen-evoked Ca²⁺ responses is consistent with this suggestion. The greater reduction of the 0.5 µg mL⁻¹ collagen-evoked Ca²⁺ response by P2X1 receptor desensitization than Panx1 inhibition (Figs. 2 and 5) suggests that ATP release involves other pathways (e.g. dense granule secretion) at this low agonist concentration. Of note, ATP release through Panx1 has also been shown to activate Ca²⁺ entry through P2X1 receptors in T cells [15]. We observed only a weak physical interaction between Panx1 and P2X1 receptors as assessed by co-immunoprecipitation (Fig. S6), although the efficacy of the antibodies employed may be limited in this assay.

Considering the substantial reduction of collagen-evoked aggregation and ATP release by Prb and Cbx, Panx1 inhibition had a smaller than predicted effect on the collagen-stimulated Ca²⁺ response. However, this apparent discrepancy is likely to be explained by considering the temporal profile of collagen-evoked Ca²⁺ influx.

Fig. 7. A model for Panx1-dependent amplification of platelet activation based on the time-course of Ca²⁺, ATP release and aggregation responses. Normalized collagen-evoked Ca²⁺ (blue), ATP release (red) and aggregation (black) traces overlaid from control (Ai) and 100 µM Prb-treated (Aii) platelets. (B) Mean time to peak Ca²⁺, ATP release and aggregation response to 0.5 µg mL⁻¹ collagen for control, Prb, Cbx and α,β-meATP-desensitized platelets. (C) Proposed pathway for the contribution of Panx1 to collagen-evoked platelet activation (DTS, dense tubular system).
ATP release and aggregation under control and Panx1-inhibited conditions as shown in Fig. 7A. Collagen stimulation of platelets promotes formation of IP3 via PLCγ [37], which leads to release of Ca2+ from the dense tubular system (DTS). We propose that this initial Ca2+ rise activates Panx1 (Fig. 7C), as described previously [14], which then releases ATP (Fig. 4) to activate P2X1 receptors, which may be co-localized (Fig. S6). Activation of P2X1 receptors amplifies the [Ca2+]i increase (Fig. 5), which promotes dense granule secretion and platelet shape change. Release of ATP and ADP from dense granules amplifies the platelet activation response further through activation of P2X1 receptors and P2Y1/12 receptors, ultimately leading to platelet aggregation (Fig. 4A). We observed that platelet aggregation is dependent on nucleotide release, which in turn is dependent on a sustained increase of intracellular Ca2+ (Fig. 7). We therefore propose that the significant reduction in platelet aggregation in the presence of Panx1 inhibitors (Fig. 4A) is due to reduced P2X1 receptor stimulation as a result of reduced ATP release through Panx1 (Fig. 7Aii). Panx1 may also contribute to platelet P2Y receptor activation either through direct passage of ATP through Panx1 or via degradation of released ATP to ADP by ectonucleotidase activity. This pathway may represent a further mechanism for amplification of platelet activation by Panx1 and may account for the greater inhibition of aggregation than predicted from the reduction in Ca2+ responses. A recent study identified that Panx3 is permeable to cAMP and may therefore act as a pathway for reducing intracellular cyclic nucleotides [49], although this has not been shown for Panx1. As our platelet preparation did not include stimuli of Gs-coupled receptors or guanylate cyclase (e.g. PG12 or NO-donors), we would not expect to see a major contribution of cyclic nucleotides efflux to the data shown in this study.

P2X1−/− mice display a resistance to thrombosis in small arteries and arterioles and their platelets have a decreased propensity to develop thrombi at arterial shear rates in vitro [21]. Similar anti-thrombotic effects were observed in vivo and in vitro for concentrations of NF449 that selectively inhibit P2X1 receptors [50]. We also show that Panx1 inhibitors reduce thrombus development on collagen surfaces under arterial shear (Fig. 6C–D) and that NF449 had no additive effect when co-applied with Prb (Fig. S7). Taken together, these findings are consistent with a role for Panx1 in ATP release and P2X1 receptor activation under flow. In these experiments Panx1 may be activated by mechanosensation, as suggested from electrophysiological recordings of heterologously expressed channels [11,36].

In conclusion, this study demonstrates that human platelets express Panx1 channels on their surface. These represent a pathway for ATP release and thus secondary activation of P2X1 receptors, which can amplify Ca2+ signals and functional responses to low concentrations of major platelet agonists. Furthermore, the contribution of Panx1 to thrombus formation at arterial shear rates make it a potential candidate for the management of thrombosis.

Addendum

K. A. Taylor designed the study, performed experiments, analyzed data and wrote the paper; J. R. Wright performed experiments and analyzed data; C. Vial performed experiments and provided reagents; R. J. Evans designed the study, provided reagents and critically read the manuscript; M. P. Mahaut-Smith designed the study, analyzed data and wrote the paper. All authors have approved the final version.

Acknowledgements

This work was funded by the British Heart Foundation (PG/11/56) and the Medical Research Council.

Disclosure of Conflict of Interests

The authors state that they have no conflict of interests.

Supporting Information

Additional Supporting Information may be found in the online version of this article:
Fig. S1. Platelet cDNA is not contaminated with genetic material from other peripheral blood cells.
Fig. S2. Generation of a HEK-293 cell line stably expressing hPanx1.
Fig. S3. Pannexin-1 does not contribute to agonist-evoked Ca2+ release from the intracellular stores of platelets.
Fig. S4. Pannexin-1 does not contribute to SOCE in platelets.
Fig. S5. The pannexin-1 inhibitors Prb and Cbx do not directly affect P2X1 receptor-mediated Ca2+ influx.
Fig. S6. Pannexin-1 and P2X1 receptors display a weak physical interaction.
Fig. S7. Co-application of the P2X1 receptor antagonist NF449 and Panx1 inhibitor Prb does not further reduce thrombus volume or height.

Table S1. Antibodies used for western blotting.

References

1 Vaiyapuri S, Jones CI, Sasikumar P, Moraes LA, Munger SJ, Wright JR, Ali MS, Sage T, Kaiser WJ, Tucker KL, Slain CJ, Bye AP, Jones S, Oviedo-Orta E, Simon AM, Mahaut-Smith MP, Gibbins JM. Gap junctions and connexin hemichannels underpin haemostasis and thrombosis. Circulation 2012; 125: 2479–91.
2 Angellino-Scherrer A, Fontana P, Burnier L, Roth I, Sugamele R, Brisset A, Morel S, Nolli S, Sutter E, Chassot A, Capron C, Borgel D, Saller F, Chanson M, Kwak BR. Connexin 37 limits
thrombus propensity by downregulating platelet reactivity. 
*Circulation* 2011; 124: 930–9.

3 Vaiyapuri S, Moraes LA, Sage T, Ali MS, Lewis KR, Mahaut-Smith MP, Ovieido-Orta E, Simon AM, Gibbins JM. Connexin40 regulates platelet function. *Nat Commun* 2013; 4: 2564.

4 Scemes E, Spray DC. Meda P, Connexins, pannexins, innexins: novel roles of "hemi-channels". *Pflugers Arch* 2009; 457: 1207–26.

5 Panchin Y, Kelmanzon I, Matz M, Lukyanov K, Usman N, Lukyanov S. A ubiquitous family of putative gap junction molecules. *Curr Biol* 2000; 10: R473–4.

6 Bruzzone R, Hormuzdi SG, Barbe MT, Herb A, Monyer H. Pannexin intermixing and cellular localization. *Proc Natl Acad Sci USA* 2003; 100: 13644–9.

7 Boassa D, Qiu F, Dahl G, Sosinsky G. Trafficking dynamics of glycosylated pannexin 1 proteins. *Cell Commun Adhes* 2008; 15: 119–32.

8 Boassa D, Ambroci C, Qiu F, Dahl G, Gaietta G, Sosinsky G. Pannexin1 channels contain a glycosylation site that targets the hexamer to the plasma membrane. *J Biol Chem* 2007; 282: 31733–43.

9 Penuela S, Bhatla R, Nag K, Laird DW. Glycosylation regulates pannexin intermixing and cellular localization. *Mol Cell Biol* 2009; 29: 4313–23.

10 Ma W, Compan V, Zheng W, Martin E, North RA, Verkrhatsky A, Surprenant A. Pannexin 1 forms an anion-selective channel. *Pflugers Arch* 2012; 463: 585–92.

11 Bao L, Locovei S, Dahl G. Pannexin membrane channels are mechanosensitive conduits for ATP. *FEBS Lett* 2004; 572: 65–8.

12 Thompson RJ, Zhou N, MacVicar BA. Ischemia opens neuronal gap junction hemichannels. *Science* 2006; 312: 924–7.

13 Sandilos JK, Chiu YH, Chekeni FB, Armstrong AJ, Walk SF, Ravichandran KS, Bayliss DA. Pannexin 1, an ATP release channel, is activated by caspase cleavage of its pore-associated C-terminal autoinhibitory region. *J Biol Chem* 2012; 287: 11303–11.

14 Locovei S, Wang J, Dahl G. Activation of pannexin 1 channels by ATP through P2Y receptors and by cytoplasmic calcium. *FEBS Lett* 2006; 580: 239–44.

15 Woehlke T, Yip L, Elkal C, Sumi Y, Chen Y, Yao Y, Insel PA, Thompson RJ, Sharkey KA. Activation of neuronal P2X7 receptor-pannexin-1 mediates death of enteric neurons during colitis. *Nat Med* 2012; 18: 600–4.

16 Vial C, Hechler B, Leon C, Cazenave JP, Gachet C. Presence of P2X1 purinoceptors in human platelets and megakaryoblastic cell lines. *Thromb Haemost* 1997; 78: 1500–4.

17 Fung CYE, Brearley CA, Farndale RW, Mahaut-Smith MP. A major role for P2X1 receptors in the early collagen-evoked intra-cellular Ca\(^{2+}\) responses of human platelets. *Thromb Haemost* 2005; 94: 37–40.

18 Fung CYE, Cendana C, Farndale RW, Mahaut-Smith MP. Primary and secondary agonists can use P2X1 receptors as a major pathway to increase intracellular Ca\(^{2+}\) in the human platelet. *J Thromb Haemost* 2007; 5: 910–7.

19 Hechler B, Lenain N, Marchese P, Vial C, Heim W, Freund M, Cazenave JP, Cattaneo M, Ruggeri ZM, Evans R, Gachet C. A role of the fast ATP-gated P2X, cation channel in thrombosis of small arteries in vivo. *J Exp Med* 2003; 198: 661–7.

20 Fung CY, Jones S, Ntrakwah A, Naseem KM, Farndale RW, Mahaut-Smith MP. Platelet Ca\(^{2+}\) responses coupled to glycoprotein VI and Toll-like receptors persist in the presence of endothelial-derived inhibitors: roles for secondary activation of P2X1 receptors and release from intracellular Ca\(^{2+}\) stores. *Blood* 2012; 119: 3613–21.

21 Niles WD, Smith DO. Anion blockers inhibit impulse-evoked quantal transmitter release at the crayfish neuromuscular junction. *J Physiol* 1982; 329: 203–10.

22 Rolf MG, Bearerley CA, Mahaut-Smith MP. Platelet shape change evoked by selective activation of P2X, purinoceptors with alpha, beta-methylene ATP. *Thromb Haemost* 2001; 85: 303–8.

23 Amisten S. A rapid and efficient platelet purification protocol for platelet gene expression studies. *Methods Mol Biol* 2012; 788: 155–72.

24 Gibbins JM. Techniques for analysis of proteins by SDS-polyacrylamide gel electrophoresis and Western blotting. *Methods Mol Biol* 2004; 273: 139–52.

25 Lalo U, Jones S, Roberts JA, Mahaut-Smith MP, Evans RJ. Heat shock protein 90 inhibitors reduce trafficking of ATP-gated P2X1 receptors and human platelet responsiveness. *J Biol Chem* 2012; 287: 32747–54.

26 Thomas D, Mason MJ, Mahaut-Smith MP. Depolarisation-evoked Ca\(^{2+}\) waves in the non-excitable rat megakaryocyte. *J Physiol* 2001; 537: 371–8.

27 Pugh N, Simpson AM, Smethurst PA, de Groot PG, Raynal N, Farndale RW. Synergism between platelet collagen receptors defined using receptor-specific collagen-mimetic peptide substrata in flowing blood. *Blood* 2010; 115: 5069–79.

28 Ma W, Hui H, Pelegin P, Surprenant A. Pharmacological characterization of pannexin-1 currents expressed in mammalian cells. *J Pharmacol Exp Ther* 2009; 328: 409–18.

29 Silverman W, Locovei S, Dahl G. Probenecid, a gout remedy, inhibits pannexin 1 channels. *Am J Physiol Cell Physiol* 2008; 295: C761–7.

30 D’Hondt C, Ponsaerts R, De Smedt B, Bultynck G, Lampens P. Pannexins, distant relatives of the connexin family with specific cellular functions? *BioEssays* 2009; 31: 953–74.

31 Bargiotas P, Krenz A, Hormuzdi SG, Ridder DA, Herb A, Barakat W, Penuela S, von Engellhardt J, Monyer H, Schwanger M. Pannexins in ischemia-induced neurodegeneration. *Proc Natl Acad Sci USA* 2011; 108: 20772–7.

32 Harper MT, Molkentin JD, Poole AW. Protein kinase C alpha enhances sodium-calcium exchange during store-operated calcium entry in mouse platelets. *Cell Calcium* 2010; 48: 333–40.

33 Toth-Zsamboki E, Oury C, Cornelissen H, De Vos R, Vermylen J, Hoylaerts MF. P2X1-mediated ERK2 activation amplifies the collagen-induced ATP release from intracellular Ca\(^{2+}\) stores. *J Biol Chem* 2003; 278: 46661–7.

34 Hashimoto Y, Togo M, Tsukamoto K, Horie Y, Watanabe T, Sugimoto T, Nishimoto T, Kitamura A, Young SH. Pannexin 1-mediated ATP release is involved in the acute aggregation and secondary agonist-induced aggregation of human platelets. *Blood* 2004; 103: 3475–84.

35 Toth-Zsamboki E, Oury C, Cornelissen H, De Vos R, Vermylen J, Hoylaerts MF. P2X1-mediated ERK2 activation amplifies the collagen-induced platelet secretion by enhancing myosin light chain kinase activation. *J Biol Chem* 2003; 278: 46661–7.

36 Xia J, Lim JC, Lu W, Beckel JM, Macarack EJ, Laties AM, Mitchell CH. Neurons respond directly to mechanical deformation with pannexin-mediated ATP release and autostimulation of P2X7 receptors. *J Physiol* 2012; 590: 2285–304.

37 Varga-Szabó D, Braun A, Nieswandt B. Calcium signaling in platelets. *J Thromb Haemost* 2009; 7: 1057–66.

38 Hashimoto Y, Togo M, Tsukamoto K, Horie Y, Watanabe T, Kurokawa K. Protein kinase C-dependent and -independent mechanisms of dense granule exocytosis by human platelets. *Biochim Biophys Acta* 1994; 1222: 56–62.

39 Barbe MT, Monyer H, Bruzzone R. Cell-cell communication beyond connexins: the pannexin channels. *Physiology (Bethesda)* 2006; 21: 103–14.

40 Lipman BI, Silverstein SC, Steinberg TH. Organic anion transport in macrophage membrane vesicles. *J Biol Chem* 1990; 265: 2142–7.

41 Pritchard JB, Sweet DH, Miller DS, Walden R. Mechanism of organic anion transport across the apical membrane of choroid plexus. *J Biol Chem* 1999; 274: 33382–7.

42 Ebihara L, Steiner E. Properties of a nonjunctional current expressed from a rat connexin46 cDNA in Xenopus oocytes. *J Gen Physiol* 1993; 102: 59–74.
Pfahnl A, Dahl G. Gating of cx46 gap junction hemichannels by calcium and voltage. *Pflugers Arch* 1999; **437**: 345–53.

Gomez-Hernandez JM, de Miguel M, Larrosa B, Gonzalez D, Barrio LC. Molecular basis of calcium regulation in connexin-32 hemichannels. *Proc Natl Acad Sci USA* 2003; **100**: 16030–5.

Allen MJ, Gemel J, Beyer EC, Lal R. Atomic force microscopy of Connexin40 gap junction hemichannels reveals calcium-dependent three-dimensional molecular topography and open-closed conformations of both the extracellular and cytoplasmic faces. *J Biol Chem* 2011; **286**: 22139–46.

Thimm J, Mechler A, Lin H, Rhee S, Lal R. Calcium-dependent open/closed conformations and interfacial energy maps of reconstituted hemichannels. *J Biol Chem* 2005; **280**: 10646–54.

Sridharan M, Adderley SP, Bowles EA, Egan TM, Stephenson AH, Ellsworth ML, Sprague RS. Pannexin 1 is the conduit for low oxygen tension-induced ATP release from human erythrocytes. *Am J Physiol Heart Circ Physiol* 2010; **299**: H1146–52.

Harper MT, Londono JE, Quick K, Londono JC, Flockerzi V, Philipp SE, Birnbaumer L, Freichel M, Poole AW. Transient receptor potential channels function as a coincidence signal detector mediating phosphatidylinerine exposure. *Sci Signal* 2013; **6**: ra50.

Ishikawa M, Iwamoto T, Fukumoto S, Yamada Y. Pannexin 3 Inhibits Proliferation of Osteoprogenitor Cells by Regulating Wnt and p21 Signaling. *J Biol Chem* 2014; **289**: 2839–51.

Hechler B, Magnenat S, Zighetti ML, Kassack MU, Ullmann H, Cazenave JP, Evans R, Cattaneo M, Gachet C. Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4',4",4‴-(carbonylbis(imino-5,1,3-benzenetriylbis(carbonylimino))tetrakis-benzene-1,3-disulfonic acid octasodium salt]. *J Pharmacol Exp Ther* 2005; **314**: 232–43.